April 5 (UPI) -- A new study has found that a drug to treat overactive bladder syndrome, or OAB, in women significantly increased the risk of developing depression within three years.
OAB affects 16 percent of adults in the United States and the prevalence increases with age, according to the National Center for Biotechnology Information.
Antimuscarinic drugs are commonly used to treat OAB because they block muscarinic receptors and prevent acetylcholine mediated bladder contractions.
Researchers analyzed data from the Taiwan Longitudinal Health Insurance Database 2005. They identified 1,952 women with OAB who took antimuscarinics and 9,760 women with OAB who did not take antimuscarinics and tracked them for three years.
The study showed that women who took antimuscarinics for OAB were 38 percent more likely to be diagnosed with depressive disorder within three years compared to those who did not receive antimuscarinics.
"This population-based retrospective cohort study found that use of antimuscarinics was associated with subsequent depressive disorder in women with overactive bladder," Li-Ting Kao, of Taipei Medical University Hospital, said in a press release.
The study was published in The Journal of Clinical Pharmacology.